IXICO (IXI) Competitors

GBX 6.67 -0.21 (-2.99%)

As of 07:59 AM Eastern

IXI vs. IMM, SBTX, OKYO, AOR, and APTA

Should you be buying IXICO stock or one of its competitors? The main competitors of IXICO include ImmuPharma (IMM), SkinBioTherapeutics (SBTX), OKYO Pharma (OKYO), AorTech International (AOR), and Aptamer Group (APTA). These companies are all part of the "biotechnology" industry.

How does IXICO compare to ImmuPharma?

IXICO (LON:IXI) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

: IXICO has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 3.183, suggesting that its stock price is 218% more volatile than the S&P 500.
: ImmuPharma has a net margin of 3,519.56% compared to IXICO's net margin of -25.27%. IXICO's return on equity of -13.74% beat ImmuPharma's return on equity.
Company Net Margins Return on Equity Return on Assets
IXICO -25.27% -13.74% -10.40%
ImmuPharma 3,519.56% -6,634.51% -43.00%
: ImmuPharma has lower revenue, but higher earnings than IXICO. ImmuPharma is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IXICO £6.53M 2.23 -£3.58M -£1.85 N/A
ImmuPharma N/A N/A -£2.51M -£0.89 N/A
: In the previous week, IXICO and IXICO both had 1 articles in the media. IXICO's average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IXICO
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ImmuPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 4.7% of IXICO shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 6.0% of IXICO shares are held by company insiders. Comparatively, 8.1% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-25.27%	-13.74%	-10.40%
ImmuPharma	3,519.56%	-6,634.51%	-43.00%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£6.53M	2.23	-£3.58M	-£1.85	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.89	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IXICO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmuPharma beats IXICO on 6 of the 10 factors compared between the two stocks.

How does IXICO compare to SkinBioTherapeutics?

SkinBioTherapeutics (LON:SBTX) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

: 4.0% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 4.7% of IXICO shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by insiders. Comparatively, 6.0% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: SkinBioTherapeutics has a beta of 0.466, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, IXICO has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
: In the previous week, IXICO had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for IXICO and 0 mentions for SkinBioTherapeutics. SkinBioTherapeutics' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.
Company Overall Sentiment
SkinBioTherapeutics Neutral
IXICO Neutral
: IXICO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SkinBioTherapeutics £4.64M 5.45 -£3.71M -£0.31 N/A
IXICO £6.53M 2.23 -£3.58M -£1.85 N/A
: SkinBioTherapeutics has a net margin of -15.01% compared to IXICO's net margin of -25.27%. SkinBioTherapeutics' return on equity of -10.01% beat IXICO's return on equity.
Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics -15.01% -10.01% -61.18%
IXICO -25.27% -13.74% -10.40%

Company	Overall Sentiment
SkinBioTherapeutics	Neutral
IXICO	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkinBioTherapeutics	£4.64M	5.45	-£3.71M	-£0.31	N/A
IXICO	£6.53M	2.23	-£3.58M	-£1.85	N/A

Company	Net Margins	Return on Equity	Return on Assets
SkinBioTherapeutics	-15.01%	-10.01%	-61.18%
IXICO	-25.27%	-13.74%	-10.40%

Summary

IXICO beats SkinBioTherapeutics on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to OKYO Pharma?

IXICO (LON:IXI) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

: IXICO has higher revenue and earnings than OKYO Pharma. IXICO is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IXICO £6.53M 2.23 -£3.58M -£1.85 N/A
OKYO Pharma N/A N/A -£6.70M -£0.01 N/A
: IXICO has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.
: OKYO Pharma has a net margin of 0.00% compared to IXICO's net margin of -25.27%. IXICO's return on equity of -13.74% beat OKYO Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
IXICO -25.27% -13.74% -10.40%
OKYO Pharma N/A -397.13% -154.72%
: 4.7% of IXICO shares are owned by institutional investors. 6.0% of IXICO shares are owned by company insiders. Comparatively, 31.9% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, IXICO had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for IXICO and 0 mentions for OKYO Pharma. IXICO's average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.
Company Overall Sentiment
IXICO Neutral
OKYO Pharma Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£6.53M	2.23	-£3.58M	-£1.85	N/A
OKYO Pharma	N/A	N/A	-£6.70M	-£0.01	N/A

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-25.27%	-13.74%	-10.40%
OKYO Pharma	N/A	-397.13%	-154.72%

Company	Overall Sentiment
IXICO	Neutral
OKYO Pharma	Neutral

Summary

IXICO beats OKYO Pharma on 8 of the 11 factors compared between the two stocks.

How does IXICO compare to AorTech International?

IXICO (LON:IXI) and AorTech International (LON:AOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

: In the previous week, IXICO had 1 more articles in the media than AorTech International. MarketBeat recorded 1 mentions for IXICO and 0 mentions for AorTech International. IXICO's average media sentiment score of 0.00 equaled AorTech International'saverage media sentiment score.
Company Overall Sentiment
IXICO Neutral
AorTech International Neutral
: 4.7% of IXICO shares are owned by institutional investors. 6.0% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: AorTech International has a net margin of 0.00% compared to IXICO's net margin of -25.27%. AorTech International's return on equity of 0.00% beat IXICO's return on equity.
Company Net Margins Return on Equity Return on Assets
IXICO -25.27% -13.74% -10.40%
AorTech International N/A N/A N/A
: AorTech International has lower revenue, but higher earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IXICO £6.53M 2.23 -£3.58M -£1.85 N/A
AorTech International £539K 0.00 N/A -£3.70 N/A

Company	Overall Sentiment
IXICO	Neutral
AorTech International	Neutral

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-25.27%	-13.74%	-10.40%
AorTech International	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£6.53M	2.23	-£3.58M	-£1.85	N/A
AorTech International	£539K	0.00	N/A	-£3.70	N/A

Summary

IXICO beats AorTech International on 6 of the 9 factors compared between the two stocks.

How does IXICO compare to Aptamer Group?

Aptamer Group (LON:APTA) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

: IXICO has higher revenue and earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptamer Group £1.38M 16.30 -£14.17M -£0.11 N/A
IXICO £6.53M 2.23 -£3.58M -£1.85 N/A
: IXICO has a net margin of -25.27% compared to Aptamer Group's net margin of -178.52%. IXICO's return on equity of -13.74% beat Aptamer Group's return on equity.
Company Net Margins Return on Equity Return on Assets
Aptamer Group -178.52% -135.35% -44.96%
IXICO -25.27% -13.74% -10.40%
: Aptamer Group has a beta of 0.903, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, IXICO has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
: 3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 4.7% of IXICO shares are owned by institutional investors. 8.8% of Aptamer Group shares are owned by insiders. Comparatively, 6.0% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: In the previous week, IXICO had 1 more articles in the media than Aptamer Group. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Aptamer Group. Aptamer Group's average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.
Company Overall Sentiment
Aptamer Group Neutral
IXICO Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	16.30	-£14.17M	-£0.11	N/A
IXICO	£6.53M	2.23	-£3.58M	-£1.85	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
IXICO	-25.27%	-13.74%	-10.40%

Company	Overall Sentiment
Aptamer Group	Neutral
IXICO	Neutral

Summary

IXICO beats Aptamer Group on 8 of the 12 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£14.55M	£450.49M	£6.30B	£2.78B
Dividend Yield	1.27%	3.86%	2.78%	6.15%
P/E Ratio	-3.61	4.22	28.45	365.90
Price / Sales	2.23	7,450.24	534.99	88,560.91
Price / Cash	2.25	13.13	43.30	27.89
Price / Book	0.34	80.23	9.82	7.59
Net Income	-£3.58M	-£96.07M	£3.55B	£5.89B
1 Month Performance	-11.60%	2.64%	5.19%	4.10%
1 Year Performance	-31.20%	71.17%	40.38%	89.74%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 6.67 -3.0%	N/A	-25.0%	£14.55M	£6.53M	N/A	89
IMM ImmuPharma	N/A	GBX 4.10 -1.5%	N/A	+31.4%	£25.55M	N/A	N/A	13
SBTX SkinBioTherapeutics	N/A	GBX 9.75 flat	N/A	N/A	£25.27M	£4.64M	N/A	11
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	£23.24M	N/A	N/A	7	Gap Down
AOR AorTech International	N/A	N/A	N/A	N/A	£19.99M	£539K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors